» Authors » Catalina Alamon

Catalina Alamon

Explore the profile of Catalina Alamon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 85
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Alamon C, Davila B, Garcia M, Nievas S, Dagrosa M, Thorp S, et al.
Mol Pharm . 2023 Apr; 20(5):2702-2713. PMID: 37013916
Glioblastoma (GBM), as the most central nervous system (CNS) intractable disease, has spoiled millions of lives due to its high mortality. Even though several efforts have been made, the existing...
2.
Alamon C, Davila B, Cerecetto H, Couto M
Chem Biol Drug Des . 2023 Feb; 101(6):1435-1445. PMID: 36746676
Moving towards high-grade glioma drug discovery, this study aimed to detect the mechanism of cellular death (apoptosis, necrosis and/or autophagy) induced by three carboranyl-based lead compounds. For that, we performed...
3.
Sanguinetti M, Silva Santos L, Dourron J, Alamon C, Idiarte J, Amillis S, et al.
Int J Mol Sci . 2022 Dec; 23(24). PMID: 36555682
Through a combination of comparative modeling, site-directed and classical random mutagenesis approaches, we previously identified critical residues for binding, recognition, and translocation of urea, and its inhibition by 2-thiourea and...
4.
Duhalde Vega M, Olivera D, Davanzo G, Bertullo M, Noya V, Fabiano de Souza G, et al.
Sci Adv . 2022 Sep; 8(38):eabn6545. PMID: 36129987
Severe COVID-19 is associated with hyperinflammation and weak T cell responses against SARS-CoV-2. However, the links between those processes remain partially characterized. Moreover, whether and how therapeutically manipulating T cells...
5.
Kovacs M, Alamon C, Maciel C, Varela V, Ibarburu S, Tarrago L, et al.
Acta Neuropathol Commun . 2021 Aug; 9(1):136. PMID: 34389060
Degeneration of motor neurons, glial cell reactivity, and vascular alterations in the CNS are important neuropathological features of amyotrophic lateral sclerosis (ALS). Immune cells trafficking from the blood also infiltrate...
6.
Alamon C, Davila B, Garcia M, Sanchez C, Kovacs M, Trias E, et al.
Cancers (Basel) . 2020 Nov; 12(11). PMID: 33218150
Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being-especially for glioblastomas-extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor...
7.
Couto M, Alamon C, Nievas S, Perona M, Dagrosa M, Teixidor F, et al.
Chemistry . 2020 Aug; 26(63):14335-14340. PMID: 32738078
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma...
8.
Couto M, Alamon C, Garcia M, Kovacs M, Trias E, Nievas S, et al.
Cells . 2020 Jun; 9(6). PMID: 32517054
One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy....
9.
Couto M, Alamon C, Sanchez C, Davila B, Fernandez M, Lecot N, et al.
Future Med Chem . 2019 Oct; 11(17):2273-2285. PMID: 31581913
Carboranylanilinoquinazoline-hybrids, developed for boron neutron capture therapy, have demonstrated cytotoxicity against murine-glioma cells with EGFR-inhibition ability. In addition, their adequate aqueous/metabolic stabilities and ability to cross blood-brain barrier make them...
10.
Couto M, Garcia M, Alamon C, Cabrera M, Cabral P, Merlino A, et al.
Chemistry . 2017 Dec; 24(13):3122-3126. PMID: 29194843
New 1,7-closo-carboranylanilinoquinazoline hybrids have been identified as EGFR inhibitors, one of them with higher affinity than the parent compound erlotinib. The comparative docking analysis with compounds bearing bioisoster-substructures, demonstrated the...